Skip to main content

Table 2 Distribution of multi-drug resistance in 103 third-generation cephalosporin-resistant E. coli isolated from humans and pigs in Korea

From: Comparative genetic characterization of CMY-2-type beta-lactamase producing pathogenic Escherichia coli isolated from humans and pigs suffering from diarrhea in Korea

Antimicrobial resistance categoriesa

No. of third-generation cephalosporin-resistant E. coli isolates shown resistance (%)

Human

Pig

Total

Total

31 (100)

72 (100)

103 (100)

Nine of classes

0 (0.0)

35 (48.6)

35 (34.0)

 AMGs, BL/BLICs, CEPs, FPIs, FQs, PCNs, PHs, Qs, TETs

0 (0.0)

35 (48.6)

35 (34.0)

Eight of classes

9 (29.0)

17 (23.6)

26 (25.2)

 AMGs, BL/BLICs, CEPs, FPIs, FQs, PCNs, Qs, TETs

9 (29.0)

2 (2.8)

11 (10.7)

 AMGs, BL/BLICs, CEPs, FPIs, FQs, PCNs, PHs, Qs

0 (0.0)

6 (8.3)

6 (5.8)

 AMGs, BL/BLICs, CEPs, FPIs, PCNs, PHs, Qs, TETs

0 (0.0)

4 (5.6)

4 (3.9)

 AMGs, BL/BLICs, CEPs, FQs, PCNs, PHs, Qs, TETs

0 (0.0)

3 (4.2)

3 (2.9)

 AMGs, CEPs, FPIs, FQs, PCNs, PHs, Qs, TETs

0 (0.0)

2 (2.8)

2 (1.9)

Seven of classes

8 (25.8)

12 (16.7)

20 (19.4)

 AMGs, BL/BLICs, CEPs, FPIs, PCNs, PHs, TETs

3 (9.7)

5 (6.9)

8 (7.8)

 AMGs, BL/BLICs, CEPs, PCNs, PHs, Qs, TETs

0 (0.0)

6 (8.3)

6 (5.8)

 AMGs, BL/BLICs, CEPs, FQs, PCNs, Qs, TETs

4 (12.9)

0 (0.0)

4 (3.9)

 AMGs, BL/BLICs, CEPs, FPIs, FQs, PCNs, Qs

1 (3.2)

0 (0.0)

1 (1.0)

 AMGs, CEPs, FQs, PCNs, PHs, Qs, TETs

0 (0.0)

1 (1.4)

1 (1.0)

Six of classes

9 (29.0)

5 (7.0)

15 (13.6)

 AMGs, BL/BLICs, CEPs, FQs, PCNs, Qs

2 (6.5)

0 (0.0)

2 (1.9)

 AMGs, BL/BLICs, CEPs, PCNs, PHs, TETs

2 (6.5)

0 (0.0)

2 (1.9)

 AMGs, BL/BLICs, CEPs, PCNs, Qs, TETs

2 (6.5)

0 (0.0)

2 (1.9)

 AMGs, CEPs, FPIs, PCNs, PHs, TETs

0 (0.0)

2 (2.8)

2 (1.9)

 AMGs, BL/BLICs, CEPs, FPIs, PCNs, TETs

0 (0.0)

1 (1.4)

1 (1.0)

 AMGs, BL/BLICs, CEPs, PCNs, PHs, Qs

1 (3.2)

0 (0.0)

1 (1.0)

 AMGs, CEPs, FPIs, PCNs, Qs, TETs

0 (0.0)

1 (1.4)

1 (1.0)

 AMGs, CEPs, FQs, PCNs, Qs, TETs

0 (0.0)

1 (1.4)

1 (1.0)

 BL/BLICs, CEPs, FPIs, PCNs, PHs, TETs

1 (3.2)

0 (0.0)

1 (1.0)

 BL/BLICs, CEPs, PCNs, PHs, Qs, TETs

1 (3.2)

0 (0.0)

1 (1.0)

Five of classes

1 (3.2)

2 (2.8)

3 (2.9)

 AMGs, BL/BLICs, CEPs, FPIs, PCNs

1 (3.2)

0 (0.0)

1 (1.0)

 AMGs, CEPs, PCNs, PHs, TETs

0 (0.0)

1 (1.4)

1 (1.0)

 AMGs, CEPs, PCNs, PHs, Qs

0 (0.0)

1 (1.4)

1 (1.0)

Four of classes

4 (12.9)

0 (0.0)

4 (3.9)

 AMGs, BL/BLICs, CEPs, PCNs

3 (9.7)

0 (0.0)

3 (2.9)

 BL/BLICs, CEPs, PCNs, Qs

1 (3.2)

0 (0.0)

1 (1.0)

Three of classes

0 (0.0)

1 (1.4)

1 (1.0)

 BL/BLICs, CEPs, PCNs

0 (0.0)

1 (1.4)

1 (1.0)

  1. aAMGs, aminoglycosides; BL/BLICs, β-lactam/β-lactamase inhibitor combinations; CEPs, cephems; FPIs, folate pathway inhibitors; FQs, fluoroquinolones; PCNs, penicillins; PHs, phenicols; Qs, quionolones; TETs, tetracyclines